Synthesis and activity of conjugates Gallic acid - GnRH-III by Júlia Piccoli & Eduardo Cilli
POSTER PRESENTATION Open Access
Synthesis and activity of conjugates Gallic acid -
GnRH-III
Júlia Pinto Piccoli*, Eduardo Maffud Cilli
From 5th Congress of the Brazilian Biotechnology Society (SBBIOTEC)
Florianópolis, Brazil. 10-14 November 2013
Background
Most of scientific studies with peptide have aim to ther-
apeutic use. New compounds have the ability to activate
or inhibit biological processes. The combination of
anticancer drugs with a molecule which recognizes
tumor specific connections, through a receiver, may pro-
vide an effective anticancer agent. The hormone GnRH-
III, analogue of the hormone GnRH (Gonadotropin
releasing hormone), has been described as inhibitor of
tumor growth, and has the possibility of use in cancer
therapy. In addition, the gallic acid and its derivatives
show great potential biological, inducing apoptosis in
tumor cells [1]. The aim of this work was to study the
feasibility of synthesis of conjugated containing Gallic
Acid and the hormone GnRH-III in order to obtain
anticancer molecules and available the activity
Methods
GnRH-III (Glp-His-Trp-Ser-His-Asp-Lys-Pro-Trp-Gly-
NH2) was synthesized using a technique called solid-
phase peptide synthesis (SPPS) [2]. The coupling of
Fmoc-amino acid and gallic acid were performed by
activation of carboxyl groups with diisopropylcarbodii-
mide (DIC)/N-hydroxybenzotriazole (HOBt). We used
the protector Trt (trityl) to protect the ε-amino group
of Lys, which allowed selective deprotection of this
group for subsequent coupling in the side chain of Lys.
Purification of the crude material was carried out in a
system of high performance liquid chromatography
(HPLC). The purity of the fractions was determined on
an analytical HPLC and confirmed by mass spectrome-
try. Mosman colorimetric test was performed in order
to detect biological activities
Results and conclusions
The synthesis of the conjugate containing gallic acid
proved to be difficult, but using optimized conditions of
deprotection of the ε-amino group of Lys, the conjugated
GnRH-III/gallic acid was obtained. According to the
results, it can be noted that the entrance of gallic acid in
question was not a major problem encountered in synth-
esis, but the removal of the protecting group of Lys. The
results showed, as expected, that the IC50 of gallic acid
was 14 ug/mL. The conjugate GnRH-III/Gallic Acid
showed IC50 much smaller than gallic acid. Apoptosis was
induced at low concentrations, showing an interesting
compound for the anticancer research.
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